"uuid:ID","instanceType","id","versionIdentifier","rationale"
"bc1c16a3-016b-4d7c-8eb3-341214e9ae1f","StudyVersion","StudyVersion_1","2","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated."
